These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 32084455)

  • 1. Cholelithiasis in patients treated with Glucagon-Like Peptide-1 Receptor: An updated meta-analysis of randomized controlled trials.
    Nreu B; Dicembrini I; Tinti F; Mannucci E; Monami M
    Diabetes Res Clin Pract; 2020 Mar; 161():108087. PubMed ID: 32084455
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety issues with glucagon-like peptide-1 receptor agonists (pancreatitis, pancreatic cancer and cholelithiasis): Data from randomized controlled trials.
    Monami M; Nreu B; Scatena A; Cresci B; Andreozzi F; Sesti G; Mannucci E
    Diabetes Obes Metab; 2017 Sep; 19(9):1233-1241. PubMed ID: 28244632
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Microvascular effects of glucagon-like peptide-1 receptor agonists in type 2 diabetes: a meta-analysis of randomized controlled trials.
    Dicembrini I; Nreu B; Scatena A; Andreozzi F; Sesti G; Mannucci E; Monami M
    Acta Diabetol; 2017 Oct; 54(10):933-941. PubMed ID: 28748377
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Major cardiovascular events, heart failure, and atrial fibrillation in patients treated with glucagon-like peptide-1 receptor agonists: An updated meta-analysis of randomized controlled trials.
    Nreu B; Dicembrini I; Tinti F; Sesti G; Mannucci E; Monami M
    Nutr Metab Cardiovasc Dis; 2020 Jun; 30(7):1106-1114. PubMed ID: 32448716
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pancreatitis and pancreatic cancer in patients with type 2 diabetes treated with glucagon-like peptide-1 receptor agonists: an updated meta-analysis of randomized controlled trials.
    Nreu B; Dicembrini I; Tinti F; Mannucci E; Monami M
    Minerva Endocrinol (Torino); 2023 Jun; 48(2):206-213. PubMed ID: 32720500
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Glucagon-like peptide-1 receptor agonists and cardiovascular outcomes in patients with and without prior cardiovascular events: An updated meta-analysis and subgroup analysis of randomized controlled trials.
    Mannucci E; Dicembrini I; Nreu B; Monami M
    Diabetes Obes Metab; 2020 Feb; 22(2):203-211. PubMed ID: 31595657
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A meta-analysis of the effects of glucagon-like-peptide 1 receptor agonist (GLP1-RA) in nonalcoholic fatty liver disease (NAFLD) with type 2 diabetes (T2D).
    Ghosal S; Datta D; Sinha B
    Sci Rep; 2021 Nov; 11(1):22063. PubMed ID: 34764398
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Glucagon-like peptide-1 receptor agonists and heart failure in type 2 diabetes: systematic review and meta-analysis of randomized and observational studies.
    Li L; Li S; Liu J; Deng K; Busse JW; Vandvik PO; Wong E; Sohani ZN; Bala MM; Rios LP; Malaga G; Ebrahim S; Shen J; Zhang L; Zhao P; Chen Q; Wang Y; Guyatt GH; Sun X
    BMC Cardiovasc Disord; 2016 May; 16():91. PubMed ID: 27169565
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glucagon-like peptide-1 receptor agonists and pancreatitis: a meta-analysis of randomized clinical trials.
    Monami M; Dicembrini I; Nardini C; Fiordelli I; Mannucci E
    Diabetes Res Clin Pract; 2014 Feb; 103(2):269-75. PubMed ID: 24485345
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glucagon-like peptide 1 receptor agonists in patients with type 2 diabetes with and without chronic heart failure: A meta-analysis of randomized placebo-controlled outcome trials.
    Ferreira JP; Saraiva F; Sharma A; Vasques-Nóvoa F; Angélico-Gonçalves A; Leite AR; Borges-Canha M; Carvalho D; Packer M; Zannad F; Leite-Moreira A; Neves JS
    Diabetes Obes Metab; 2023 Jun; 25(6):1495-1502. PubMed ID: 36722252
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Glucagon-like peptide-1 receptor agonists and risk of acute pancreatitis in patients with type 2 diabetes.
    Storgaard H; Cold F; Gluud LL; Vilsbøll T; Knop FK
    Diabetes Obes Metab; 2017 Jun; 19(6):906-908. PubMed ID: 28105738
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of glucagon-like peptide-1 receptor agonists on cardiovascular risk: a meta-analysis of randomized clinical trials.
    Monami M; Dicembrini I; Nardini C; Fiordelli I; Mannucci E
    Diabetes Obes Metab; 2014 Jan; 16(1):38-47. PubMed ID: 23829656
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of Glucagon-like Peptide-1 Receptor Agonists on All-cause Mortality and Cardiovascular Outcomes: A Meta-analysis.
    Peterson SC; Barry AR
    Curr Diabetes Rev; 2018; 14(3):273-279. PubMed ID: 28413990
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Update in Cardiovascular Safety of Glucagon Like Peptide-1 Receptor Agonists in Patients With Type 2 Diabetes. A Mixed Treatment Comparison Meta-Analysis of Randomised Controlled Trials.
    Al Yami MS; Alfayez OM; Alsheikh R
    Heart Lung Circ; 2018 Nov; 27(11):1301-1309. PubMed ID: 29887418
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumour Risk with Once-Weekly Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes Mellitus Patients: A Systematic Review.
    Guo X; Yang Q; Dong J; Liao L; Zhang W; Liu F
    Clin Drug Investig; 2016 Jun; 36(6):433-41. PubMed ID: 26979594
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cardiovascular Safety of Glucagon-Like Receptor 1 Agonists in Patients With Type 2 Diabetes and Peripheral Arterial Disease: A Meta-Analysis of Randomized Controlled Trials.
    Ashraf MT; Ali A; Ahmed N; Shakeel Khan MK; Usman M
    Am J Ther; 2024 Jul-Aug 01; 31(4):e483-e486. PubMed ID: 38976535
    [No Abstract]   [Full Text] [Related]  

  • 17. Progression of retinopathy with glucagon-like peptide-1 receptor agonists with cardiovascular benefits in type 2 diabetes - A systematic review and meta-analysis.
    Yoshida Y; Joshi P; Barri S; Wang J; Corder AL; O'Connell SS; Fonseca VA
    J Diabetes Complications; 2022 Aug; 36(8):108255. PubMed ID: 35817678
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Strategies for Appropriate Selection of SGLT2-i vs. GLP1-RA in Persons with Diabetes and Cardiovascular Disease.
    Dhindsa DS; Mehta A; Sandesara PB; Thobani A; Brandt S; Sperling LS
    Curr Cardiol Rep; 2019 Jul; 21(9):100. PubMed ID: 31352613
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glucagon-like peptide-1 receptor agonists and risk of bone fracture in patients with type 2 diabetes: A meta-analysis of randomized controlled trials.
    Cheng L; Hu Y; Li YY; Cao X; Bai N; Lu TT; Li GQ; Li N; Wang AN; Mao XM
    Diabetes Metab Res Rev; 2019 Oct; 35(7):e3168. PubMed ID: 30974033
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Glucagon-like peptide-1 receptor agonists and risk of thyroid cancer: A systematic review and meta-analysis of randomized controlled trials.
    Silverii GA; Monami M; Gallo M; Ragni A; Prattichizzo F; Renzelli V; Ceriello A; Mannucci E
    Diabetes Obes Metab; 2024 Mar; 26(3):891-900. PubMed ID: 38018310
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.